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Summary.-This paper is aimed at investigating how metastatic tumour growth
influenced the haemostatic system of the host. Blood platelet count, blood fibrinogen
level, the activated partial thromboplastin time (APTT) and the prothrombin time
(PT) were determined at various intervals during growth and metastasis of a murine
fibrosarcoma (mFS6) or one of its sublines with different metastatic capacity.
Progressive thrombocytopenia and increase infibrinogen level were observed during
development of the tumour in all the animal groups studied, irrespective of the
metastatic potential of the various sublines. No significant changes were observed in
the PT or APTT values. These data support the concept that primary rather than
metastatic growth influences the haemostatic system of tumour-bearing animals.
NEOPLASTIC DISEASES are often accom-
panied by haemorrhagic and/or thrombo-
embolic complications (Rasche & Dietrich,
1977; Donati & Poggi, 1980). The mech-
anism of the involvement of haemostatic
factors in human neoplasia is, however,
difficult to study, in view of the many
interfering factors, such as chemotherapy,
immunotherapy, surgery, or radiotherapy
which by themselves can modify the
haemostatic system. Animal studies are
therefore needed in this context.
In a limited number of experimental
tumours the host's haemostatic system
has been followed during primary and
metastatic growth. Among murine meta-
stasizing tumours, the Lewis lung carcin-
oma (3LL) and the JW sarcoma have been
characterized from this viewpoint. Al-
though they induced somewhat different
types of coagulopathy in their recipients,
both tumours were accompanied by
marked thrombocytopenia and a gradual
increase in blood fibrinogen level. These
changes appeared during the period of
lung metastatic growth after i.m. im-
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plantation of tumour cells (Poggi et al.,
1977; Chmielewska et al., 1980) but it is
not yet clearly established whether the
metastases areindeedresponsible for them.
In the 3LL system, thrombocytopenia,
hyperfibrinogenaemia and haemolytic
microangiopathic anaemia only occurred
in experimental conditions where the
primary tumour was present; they were
not seen during lung colony growth after
i.v. injection of cancer cells or during
metastatic growth from i.m. implanted
3LL cells, if the primary had been sur-
gically removed (Poggi et al., 1980).
Therefore, the pathogenesis of these
changes remains open to investigation.
Recently, in several murine tumour
models, sublines with different metastatic
potential have been derived from the same
parent line. This system may represent an
interesting new tool with which to study
biological processes associated with cancer-
cell dissemination (Poste & Fidler, 1980).
In this paper we have investigated the
blood coagulation changes during the
growth and metastasis of a murine fibro-
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TABLE.-Metws-tasizing capacity of the rnFS6 sarcoma and its sublines from mnetasta8se8*
Tumour MSTt
line (days)
mFS6 33
(25-50)
M4 36
(30-49)
M8 35
(26-47)
AI9 36
(25-52)
Day on which
50% of
injected
mice showed
a palpable
tumour
14
13
13
15
Mice with
metastases/
total
17/32
13/14§
1/16§
No.
metastases/
mouse
(± s.e.)
3-3+0-3
Metastasis
weight/
mouse
(mg±s.e.)
18-2+5-4
16-7 _3-61 122-5 +38-51
1-0 0-5
0/15§
* 104 tumour cells were injected i.m. and metastases were examined at death (Giavazzi et al., 1980).
t Median survival time (with range).
I P < 0-01 compared to mFS6, Duncan's new multiple-range test.
§ P < 0-01 compared to primary mFS6, Fisher's exact test.
sarcoma and of 3 of its sublines with
different metastatic capacity.
MATERIALS AND METHODS
Animals and tumours.-Male C57BL/6J
mice weighing 20-25 g at the start of the
experiment were obtained from Charles
River, Calco, Italy. The benzo(a)pyrene-
induced mFS6 sarcoma, previously described
in detail (Mantovani, 1978) spontaneously
metastasizes to the lungs in about half of the
i.m. injected syngeneic C57BL/6 hosts. It
was used at its 10-20th passage. Cells from
mFS6 and 3 sublines obtained from spon-
taneous lung nodules (M4, M8, M9) were
studied (Giavazzi et al., 1980). The meta-
static capacity of these sublines is shown in
the Table. Tumours obtained 2-3 weeks after
implantation were minced with scissors and
disaggregated by exposure to 0.1% trypsin
in Eagle's basal medium (BEM). The cells
were washed twice with 50 ml BEM and
resuspended in the same medium at the
desired concentration. The tumour-cell sus-
pension (104 cells) was injected i.m. in the
right hind thigh of syngeneic mice. At spon-
taneous death, the number and weight of
lung secondaries were measured as previously
described (Mantovani, 1978).
Blood coagulation a"says.-For each series
ofexperiments, groups of4 tumour-implanted
mice from mFS6, M4, M8 and Mg and from
control animals, were killed at various inter-
vals during the whole period of tumour
development. In some experiments blood was
collected by intracardiac puncture from open-
chested animals under light ether anaes-
thesia. For anticoagulation, 9 parts of blood
were mixed directly with 1 part 0-126M
trisodium citrate in a disposable plastic
syringe.
In other experiments native blood was
collected from the retro-orbital plexus by
means of a 2Ou1 Konstriktions pipette (H.
Pedersen, Oslo, Norway).
Blood platelets were counted by phase
microscopy after dilution of blood with
ammonium oxalate with a capillary standard-
ized pipetting system (Unopette, Becton
Dickinson Italia, Novate Milanese, Italy).
Blood fibrinogen concentration was meas-
ured by the Fibrin Polymerization Time
(FPT) test adapted to mouse blood (Poggi
et al., 1977).
For activated partial thromboplastin time
(APTT) and prothrombin time (PT) platelet-
poor plasma (PPP) was obtained by centri-
fuging citrated blood in an Eppendorf centri-
fuge for 3 min at 12,000 g.
APTT was measured using Thrombofax
(Ortho Cilag Chemie, Milan, Italy) as the
platelet substitute and 0-5% Kaolin as
activating material.
PT was measured using commercially
available rabbit-brain thromboplastin (Hy-
land, Profarco, Milan, Italy (Poggi et al.,
1979).
RESULTS
Fig. 1 shows the evolution of platelet
counts and fibrinogen levels during the
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FIG. 1.-Course of blood platelet count and
blood fibrinogen level in mice at different
intervals during growth ofmFS6 or its sub-
lines. Each result is expressed as a percen-
tage of the value obtained from a paired
control animal, tested simultaneously.
Means + s.e. of data from 4 animals per
group.
development of mFS6 and its 3 sublines.
In all instances the platelet count started
to drop during the 3rd week after tumour-
cell implantation, and gradually fell to
20-30% of the controls tested simul-
taneously. In animals implanted with the
parent line or M8 or Mg sublines, blood
fibrinogen was already higher than in con-
trols one week after implantation, de-
creased one week later and increased again
in the subsequent part of the observation
period. In M4-bearing mice a progressive
increase in blood fibrinogen level was
observed, starting from the second week
after tumour implantation.
Fig. 2 shows the PT and APTT values
at 3 intervals during metastatic growth of
mF86 and its sublines. As regards PT, no
changes were observed in any of the
groups; the same was true for APTT,
though with somewhatgreaterfluctuation,
neverexceeding 30-40%/ ofcontrol values.
DISCUSSION
This study shows that in abenzopyrene-
induced fibrosarcoma ofmice, the develop-
ment ofthe tumour and the appearance of
FS6 Mg M8 M4
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FIG. 2.-PT and APTT ratios in plasma of
mice at 3 intervals during metastatic
growth ofmFS6 or its sublines. Results are
expressed as the ratio between clotting time
ineachtumour-bearinganimalanditspaired
control. Means + s.e. of data from 4 animals
per group.
lung metastases was accompanied by a
drop in blood platelet count and an in-
crease in fibrinogen levels. In contrast, no
significant changes were observed in PT
and APTT, two tests which assess the
extrinsic and intrinsic blood clotting path-
ways respectively. This indicates that the
reduction in blood platelet count was not
accompanied by clear signs of hypo-
coagulability, as would occur if the
thrombocytopenia were due to consump-
tion coagulopathy.
In the only two other murine meta-
stasizing tumours investigated so far, the
3LL and the JW sarcoma, thrombocyto-
penia also occurred. For the 3LL, although
low-grade intravascular coagulation was
suspected, kinetic studies with radio-
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labelled platelets and marrow examina-
tions clearly indicated that the drop in
platelet count was due to impaired syn-
thesis rather than increased consumption
(Poggi et al., 1977).
In the JW sarcoma, thrombocytopenia
was not accompanied by any signs of
intravascular coagulation (Chmielewska
et al., 1980). The increase in fibrinogen
level observed in mFS6 appears to be due
more to an acute-phase reaction than to a
synthetic response in low-grade intra-
vascular clotting. This contention is in-
directly supported by the fact that hyper-
fibrinogenaemia has been reported in
several rat and murine tumours, in asso-
ciation with either increased or normal
fibrinogen turnover (Hilgard et al., 1973;
Poggi et al., 1977; Chmielewska et al.,
1980) and with different patterns of fibrin
deposition around the tumour. That
thrombocytopenia and hyperfibrinogen-
aemia, at least in the 3LL model, were not
due to consumption coagulopathy is fur-
ther indicated by the fact that they were
not corrected by anticoagulants or platelet
aggregation inhibitors given chronically
to tumour-bearing mice (Poggi etal., 1980).
PT and APTT were normal also in the
3LL and JWS models. Thus mFS6, a
chemically induced tumour, provoked
essentially the same haemostatic changes
as 3LL and JWS, ofspontaneous origin.
The availability of cells derived from
the same parent line but with different
metastatic capacity, enables us to study
metastasis-related biological properties
with new perspectives. The sublines of
mFS6 used in this study had markedly
different metastatic potential (Giavazzi
et al., 1980) M8 and Mg being virtually
unable to give metastases and M4 being
much more metastatic than the parent
line. Our results indicate that, regardless
of their dissemination capacity, the mFS6
sublines induced the same haemostatic
changes in the host as the parent line.
Since these cells did not differ as regards
primary growth, our observations strongly
support the concept that thrombocyto-
penia and hyperfibrinogenaemia are in-
duced by the presence of the primary
tumour rather than by metastatic nodules.
It has indeed been reported in the 3LL
system that thrombocytopenia and hyper-
fibrinogenaemia were only seen when the
primary tumour was present, and were
not modified by a treatment, such as
warfarin anticoagulation, which selec-
tively reduced metastatic growth (Poggi
et al., 1980).
When tested for their procoagulant
activity in vitro, the M8 and Mg sublines
showed a much greater clot-promoting
capacity than M4 or the parent line
(Colucci et al., 1980). Since such dis-
crepancies were not reproduced when the
same cells were given in vivo to mice, we
conclude that no simple correlation exists
between cancer-cell procoagulant activity
as measured in vitro and the respective
tumour-associated changes in the host's
haemostatic system.
In conclusion, this study shows that
some haemostatic changes may occur in
animals bearing an experimental tumour
whatever the pattern of its spontaneous
metastasis.
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